ArticleSurgical endoscopy2026
Pre-operative endoscopic assessment and MRI as predictors of pathological complete response and long-term survival in locally advanced rectal cancer after neoadjuvant therapy.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe optimal modality for predicting pathological complete response (pCR) after neoadjuvant therapy in rectal cancer remains uncertain. This study evaluated the ability of pre‑operative endoscopy and magnetic resonance imaging (MRI) to predict pCR and long‑term survival in stage II/III rectal cancer following neoadjuvant treatment.
methodsRetrospective cohort study of a prospectively maintained database of patients with stage II/III rectal cancer undergoing neoadjuvant therapy followed by surgery between 2016 and 2024 at a single institution. Patients underwent pre-operative endoscopic assessment and MRI restaging 4-8 weeks after completion of their neoadjuvant therapy, followed by surgery at 8-12 weeks. Endoscopic response was classified according to the Memorial Sloan Kettering schema. Strictures were classified as a separate phenotype. MRI tumour response was classified according to the tumour regression grade (TRG) score. Primary outcome was the pCR rate.
resultsOf 203 patients, the overall pCR rate was 19.7%. pCR rates were 76.4% for cCR, 47.6% for nCR, 50% for strictures and 0% for iCR. Endoscopic response showed a greater discrimination for pCR compared to MRI TRG, (AUC 0.92 vs. 0.65, z = 5.74, p < 0.001). When cCR, nCR and strictures were grouped as "good endoscopic response" and iCR as "poor response", 8-year OS was 80.1% versus 62.3% (χ
conclusionsEndoscopic assessment provides a stronger predictor of pCR compared to MRI alone. Survival differences by response category suggest that intrinsic tumour biology, rather than delays in surgery, drives outcomes and supports careful WW surveillance for selected patients.
Indexed as
Identifiers
42816635What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.